09:59 AM EST, 11/06/2025 (MT Newswires) -- Xeris Biopharma Holdings ( XERS ) shares were down more than 14% in recent Thursday trading after the company posted its Q3 results.

The company reported a breakeven Q3, compared with a net loss of $0.11 per diluted share a year earlier.

Three analysts polled by FactSet expected breakeven results.

Revenue for the quarter ended Sept. 30 was $74.4 million, up from $54.3 million a year earlier.

Analysts polled by FactSet expected $74.2 million.

Xeris Biopharma ( XERS ) narrowed its 2025 revenue outlook to between $285 million and $290 million, from the previous range of $280 million to $290 million. Analysts polled by FactSet expect $286.5 million.

Price: 8.12, Change: -1.75, Percent Change: -17.73